Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux vs low molecular weight heparin before CABG in NSTE-ACS
ChiCTR2200060740Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) comparing Fondaparinux arm with Low molecular weight heparin arm (2 arms). Primary endpoint: Major cardiovascular events before CABG. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
fondaparinuxlow molecular weight heparin calcium
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on ChiCTR2200060740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060740.